11:48 AM EST, 11/14/2025 (MT Newswires) -- (Updates headline and first paragraph with Scholar Rock's ( SRRK ) recent stock movement and last two paragraphs with details of the Type A meeting with the US FDA on apitegromab.)

Scholar Rock ( SRRK ) shares rose nearly 25% in Friday trading after the company reported Q3 results and said it recently concluded a "constructive" Type A meeting with the US Food and Drug Administration on its spinal muscular atrophy treatment, apitegromab.

Scholar Rock ( SRRK ) posted a Q3 net loss of $0.90 per diluted share, widening from a loss of $0.66 a year earlier.

Analysts polled by FactSet expected a loss of $0.84.

The biopharmaceutical company said it had $369.6 million in cash, cash equivalents, and marketable securities as of Sept. 30. The company expects its current cash position to fund operations into 2027.

At the FDA meeting on Wednesday, Catalent Indiana, part of Novo Nordisk (NVO), joined Scholar Rock ( SRRK ) to present progress on the remediation plan for the facility used for apitegromab production. The site is on track for reinspection by the end of 2025.

Scholar Rock ( SRRK ) said it expects to resubmit the biologics license application for apitegromab and, following approval, launch the treatment in the US in 2026.

Price: 37.57, Change: +7.50, Percent Change: +24.94